

July 28, 2003
AnGes MG, Inc.

Key Japanese patent issued covering HGF gene therapy

AnGes MG today announced the issuance of a Japanese patent (JP3431633B2) covering HGF gene therapy.

Specifically, it claims a medicament for treating disease for which HGF is effective, comprising intramuscular administration of an expression vector containing an HGF gene. On the basis of the Company's R&D in treatment of peripheral arterial diseases / ischemic heart disease, the patent will support the Company's expanding the medicine's scope of applications, as well as promote the Company's projects related to clinical trials for HGF genetic medicine.

Corresponding patents were established abroad to effectively protect the clinical development globally.

US patent 6248722

Australian patent 745887

New Zealand patent 315769

Taiwanese patent 165197

In addition, patents are pending in Europe, Canada, China, and Korea.

Finally, additional medical use patent applications were filed subsequently to reinforce this key patent, for enhancing HGF gene therapy and expanding its scope.